Abstract 390P
Background
The intensive incidence rate of oropharyngeal cancer in Uzbekistan has increased over the past 7 years from 1.4 to 2.0 per 100,000 population in 2022, and the proportion of active detection has increased from 25.9 to 32.9%.
Methods
A retrospective analysis of the causes and prevalence of oropharyngeal cancer in the Republic of Uzbekistan was performed. The object of the study were 582 patients from database of RSSPMC of Oncology and Radiology of Uzbekistan who were treated for the period 2020-2022. The study of risk factors was carried out according to gradations: smoking, use of a local variety of tobacco - nasvay, alcohol consumption, a history of trauma, a resident of an urban area, working in gas contamination conditions and dustiness. There were 471 men (80.9%), women - 101 (19.1%). The mean age was 47.3±1.5.
Results
A study of geographical indicators demonstrated that the most common oropharyngeal cancer caused by the use of nasvay occurred in patients from the eastern and southern regions of the republic - 327 (56.2%). In these patients, the average duration of tobacco use was more than 7 years. In contrast, poor climatic conditions caused the development of oral cancer in 89 (15.3%) patients from the Aral Sea region (northwest). The remaining 166 (28.5%) patients were in the central regions of Uzbekistan. When studying risk factors, the vast majority of patients (411 (70.6%)) used nasvay as a bad habit. At the same time, 174 (42.3%) of 411 patients also had smoking and alcohol consumption. Despite the impact of the dusty climate in the Aral Sea zone, 81 (91.0%) patients had a history of alcohol consumption, 19 (21.3%) - smoking. 218 (37.5%) urban residents developed oral cancer due to bad habits (smoking - 174, alcohol - 147, nasvay - 53).
Conclusions
Thus, the analysis of the epidemiological aspects of the development of oral cancer in Uzbekistan indicates that this disease is quite widespread and tends to grow. The main factor is bad habits, in particular the widespread use of nasvay. Only, in the urban population, the influence of nasvay on the development of cancer becomes less, but due to the prevalence of smoking and alcohol abuse, it requires further study to identify specific ways to manage oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract